Barriers and facilitators for family physicians prescribing opioid agonist therapy in Saskatchewan

被引:0
|
作者
Nguyen, Teresa [1 ]
Bareham, Julia [2 ]
Halpape, Katelyn [3 ]
机构
[1] Loblaw Pharm Saskatoon, Saskatoon, SK, Canada
[2] Univ Saskatchewan, RxFiles Acad Detailing Program, Saskatoon, SK, Canada
[3] Univ Saskatchewan, Coll Pharm & Nutr, Saskatoon, SK, Canada
关键词
COLLABORATIVE CARE; BUPRENORPHINE; EXPERIENCE; ABSTINENCE; ADDICTION; METHADONE;
D O I
10.46747/cfp.7004e52
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objective To explore barriers and facilitators for family physicians in Saskatchewan prescribing opioid agonist therapy (OAT). Design Self-administered postal survey. Setting Family medicine practices in Saskatchewan. Participants A total of 218 Saskatchewan family physicians who were not authorized to prescribe OAT as of June 2022. Main outcome measures Descriptive and inferential statistics of physicians' self-reported barriers to and facilitators of prescribing OAT for opioid use disorder (OUD). Results Most respondents (84.8%) had some comfort with diagnosing OUD. However, more than half (58.3%) did not feel confident or knowledgeable about prescribing OAT. Barriers to OAT prescribing included lack of time, incomplete training requirements, lack of interest, insufficient funding or support, feeling overwhelmed, and perceiving that OAT does not work and thus is not necessary. Physicians working in core neighbourhoods and those receiving fee-for-service compensation reported the least available time to prescribe OAT. Conversely, physicians working in interdisciplinary team settings had increased time for OAT prescribing compared with physicians in other settings. Having a close personal relationship with someone with OUD was correlated with increased comfort in diagnosing OUD as well as with knowledge about and confidence in prescribing OAT. Themes identified as facilitators to increasing OAT prescribing included the addition of resources and supports, increased training, more awareness about OUD and OAT, enhanced compensation, and altered prescribing regulations. Conclusion Despite the presence of several real and perceived barriers limiting OAT prescribing by Saskatchewan family physicians, there are family physicians interested in providing this therapy. Increased clinical resources and support, including increased interdisciplinary practice, are actionable steps that should be considered by policy decision makers to address this issue. Additionally, increased OUD and OAT education, which includes the perspectives of those with lived experience of OUD, would help address physician confidence, knowledge, and awareness in this area.
引用
收藏
页码:e52 / e60
页数:9
相关论文
共 50 条
  • [31] A qualitative analysis of barriers to opioid agonist treatment for racial/ethnic minoritized populations
    Husain, Jawad M.
    Cromartie, Devin
    Fitzelle-Jones, Emma
    Brochier, Annelise
    Borba, Christina P. C.
    Montalvo, Cristina
    JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2023, 144
  • [32] Psychotherapeutic benefits of opioid agonist therapy
    Tenore, Peter L.
    JOURNAL OF ADDICTIVE DISEASES, 2008, 27 (03) : 49 - 65
  • [33] Barriers and Facilitators to DATA Waivered Providers Prescribing Buprenorphine: A Qualitative Analysis Applying the Theory of Planned Behavior
    Bapat, Shweta
    Washburn, Micki
    Tata, Vaishnavi
    Fleming, Marc
    Abughosh, Susan M.
    Essien, E. James
    Thornton, Douglas
    SUBSTANCE USE & MISUSE, 2022, 57 (12) : 1761 - 1771
  • [34] Barriers and Facilitators to the Use of Medications for Opioid Use Disorder: a Rapid Review
    Mackey, Katherine
    Veazie, Stephanie
    Anderson, Johanna
    Bourne, Donald
    Peterson, Kim
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2020, 35 (SUPPL 3) : 954 - 963
  • [35] Barriers and Facilitators to the Use of Medications for Opioid Use Disorder: a Rapid Review
    Katherine Mackey
    Stephanie Veazie
    Johanna Anderson
    Donald Bourne
    Kim Peterson
    Journal of General Internal Medicine, 2020, 35 : 954 - 963
  • [36] Clinical Outcomes of Benzodiazepine Prescribing for People Receiving Opioid Agonist Treatment: A Systematic Review of the Evidence
    Matheson, Catriona
    Vucic, Chris
    Dumbrell, Josh
    Robertson, Roy
    Ritchie, Trina
    Duncan, Clare
    Kessavalou, Karthigayan
    Woolston, Caroline
    Schofield, Joe
    PHARMACY, 2024, 12 (05)
  • [37] Evaluating comparative effectiveness of psychosocial interventions for persons receiving opioid agonist therapy for opioid use disorder: protocol for a systematic review
    Rice, Danielle B.
    Hutton, Brian
    Poulin, Patricia
    Sproule, Beth A.
    Wolfe, Dianna
    Moher, David
    Thavorn, Kednapa
    Garber, Gary
    Taha, Sheena
    Porath, Amy
    Willows, Melanie
    Esmaeilisaraji, Leila
    Yazdi, Fatemeh
    Shea, Beverley
    Skidmore, Becky
    Corace, Kimberly
    BMJ OPEN, 2018, 8 (10):
  • [38] Regulatory and allocative policies inform access to opioid agonist therapy
    Priest, Kelsey C.
    ADDICTION, 2020, 115 (12) : 2255 - 2256
  • [39] Maternity Care and Buprenorphine Prescribing in New Family Physicians
    St Louis, Joshua
    Eden, Aimee R.
    Morgan, Zachary J.
    Barreto, Tyler W.
    Peterson, Lars E.
    Phillips, Robert L., Jr.
    ANNALS OF FAMILY MEDICINE, 2020, 18 (02) : 156 - 158
  • [40] Barriers to Post-Acute Care for Patients on Opioid Agonist Therapy; An Example of Systematic Stigmatization of Addiction
    Wakeman, Sarah E.
    Rich, Josiah D.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2017, 32 (01) : 17 - 19